Cardea Receives a $1.1 million Grant from the Bill & Melinda Gates Foundation

Cardea, a Serra Capital II and Serra Capital II Follow-on-Fund company, announced on May 3 that it had received a $1.1 million grant from the Bill and Melinda Gates Foundation. Cardea, which is integrating biology with modern electronics, said the grant will fund work that someday could detect infectious diseases like COVID and cancer via odor. Emerging countries will be targeted for this project, with the goal to verify that Cardea can deliver bio-sensing receptors that work as an “electronic nose” through integration into its Biosignal Processing Unit platform, or BPU.

“Using our BPU platform to bring novel and feasible diagnosis capabilities to developing countries was a major driver as to why we started Cardea in the first place,” said Michael Heltzen, chief executive of the company. “Developing an electronic nose with the potential to diagnose diseases like COVID, malaria, cancer and so on is literally a dream come true.”

To view the entire story, follow here.